Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 121

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1A
Chunk 121
---
Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report, including our audited financial statements and the related notes, as well as our other public filings with the SEC, before deciding to invest in our common stock. If any of the following risks are realized, our business, financial condition, results of operations and prospects, as well as the price of our common stock, could be materially and adversely affected.

SUMMARY OF RISK FACTORS

•We have a limited operating history, are not profitable and may never become profitable.

•We have expressed substantial doubt about our ability to continue as a going concern.

•We may not realize the anticipated benefits of the Kintara Merger.

•Our business is heavily dependent on the successful development, regulatory approval and commercialization of our product candidates.

•We will require substantial additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of any of our product candidates.

•Our product candidates will face significant competition and may be unable to compete effectively.

•Various government regulations could limit or delay our ability to develop and commercialize our products or otherwise negatively impact our business.

•The commercial potential of our products is difficult to predict. The market for any product, or for companion animal diagnostics and medical devices overall, is uncertain and may be smaller than we anticipate, which could significantly and negatively impact our revenue, results of operations and financial condition.

•Our ability to obtain intellectual property protection for our products is limited.

•We will rely on third parties to conduct certain portions of our development activities. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize our product candidates.

43

•If we fail to attract and keep key personnel and members of management, we may be unable to successfully develop any of our existing or future product candidates, conduct our in-licensing and development efforts and commercialize any of our existing or future products.

•Any failure by us to protect our intellectual property rights or maintain the right to use certain intellectual property may negatively affect our ability to compete.

•Failure to complete the Kineta Merger could negatively impact our stock price, future business and financial results. 

•Even if we consummate the Kineta Merger, we may not realize the anticipated benefits of the Kineta Merger. 

•We expect to